STRN3: A Potential Drug Target and Biomarker for Stroke (G29966)

Target Name: STRN3

NCBI ID: G29966

STRN3

STRN3: A Potential Drug Target and Biomarker for Stroke

Stroke is a leading cause of death and disability worldwide, affecting millions of people each year. Despite advances in treating stroke, the survival rate remains poor, and the recurrence rate is high. Therefore, there is a need for new treatments and better understanding of the underlying mechanisms to improve outcomes.

STRN3, a protein known as striatin-3, has been identified as a potential drug target and biomarker for stroke. Striatin-3 is a nuclear protein that is expressed in various tissues and plays a role in the regulation of cellular processes, including cell growth , apoptosis, and inflammation.

Recent studies have shown that Striatin-3 is involved in the regulation of blood-brain barrier (BBB) 鈥嬧?媐unction, which is critical for the delivery of therapeutic agents to the site of stroke. The BBB is a specialized barrier that separates the brain from the blood and plays a vital role in maintaining the integrity of the central nervous system (CNS).

STRN3 has been shown to regulate the expression of genes involved in the formation of the BBB, as well as its function. This suggests that Striatin-3 may be a useful target for drugs that are designed to improve BBB function and enhance the delivery of therapeutic agents to the site of stroke.

In addition to its potential as a drug target, Striatin-3 has also been shown to be a potential biomarker for stroke. The use of biomarkers, such as STRN3, can help doctors diagnose and monitor the progression of stroke more accurately.

Studies have shown that Striatin-3 is expressed in the brains of individuals with ischemic stroke, which is the most common type of stroke. In addition, individuals with basal spasticity, which is a type of non-ischemic stroke, also had increased levels of Striatin-3 in their brains.

Ischemic stroke, which is caused by a blockage of blood flow to the brain, is the most common form of stroke and is associated with the highest mortality rate. The recurrence rate of ischemic stroke is high, and the treatment options are limited. Therefore, there is a need for new treatments that can improve outcomes and reduce the recurrence rate.

STRN3 has been shown to be involved in the regulation of cellular processes that may be involved in the recurrence of ischemic stroke. For example, studies have shown that Striatin-3 can inhibit the activity of a protein called FAK, which is involved in the formation of blood-brain barrier cells that may contribute to the recurrence of ischemic stroke.

In addition, Striatin-3 has also been shown to regulate the expression of genes involved in the formation of glial cells, which are the support cells for the central nervous system. The recurrence of ischemic stroke is thought to involve the destruction of glial cells, and therefore

Protein Name: Striatin 3

Functions: Binds calmodulin in a calcium dependent manner. May function as scaffolding or signaling protein

The "STRN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STRN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets